The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
Clicks: 157
ID: 269547
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
157 views
14 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #53 of 77 articles by views in Frontiers in psychiatry
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor agonist, has emerged as a promising drug for AUD. The use of this drug remains controversial, in part due to uncertainty r …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (46 words).
Try re-searching for a better abstract.
| Reference Key |
r2019frontiersthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | de Beaurepaire R;Sinclair JMA;Heydtmann M;Addolorato G;Aubin HJ;Beraha EM;Caputo F;Chick JD;de La Selle P;Franchitto N;Garbutt JC;Haber PS;Jaury P;Lingford-Hughes AR;Morley KC;Müller CA;Owens L;Pastor A;Paterson LM;Pélissier F;Rolland B;Stafford A;Thompson A;van den Brink W;Leggio L;Agabio R;; |
| Journal | Frontiers in psychiatry |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.